{"id":41971,"date":"2025-09-22T15:13:05","date_gmt":"2025-09-22T07:13:05","guid":{"rendered":"https:\/\/flcube.com\/?p=41971"},"modified":"2025-09-22T15:13:06","modified_gmt":"2025-09-22T07:13:06","slug":"biogen-acquires-alcyone-therapeutics-to-drive-thecaflex-drx-implant-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41971","title":{"rendered":"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development"},"content":{"rendered":"\n<p><strong>Biogen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>) announced the acquisition of Massachusetts\u2011based <strong>Alcyone Therapeutics<\/strong>. The deal centers on the joint development of <strong>ThecaFlex\u202fDRx<\/strong>, an investigational implantable subcutaneous port\u2011catheter system designed for intrathecal delivery of antisense oligonucleotide (ASO) therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-thecaflex-drx-matters\">Why ThecaFlex\u202fDRx Matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Experience<\/strong> \u2013 Replaces the need for repeated lumbar punctures in patients requiring long\u2011term intrathecal ASO administration.<\/li>\n\n\n\n<li><strong>Access &amp; Adherence<\/strong> \u2013 Aims to improve treatment adherence and broaden access to intrathecal therapies for neurological disorders.<\/li>\n\n\n\n<li><strong>Device\u2011Therapy Synergy<\/strong> \u2013 Represents a strategic expansion of Biogen\u2019s drug\u2011device combination portfolio, aligning with its broader pipeline of injectable and intrathecal products.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquisition<\/strong><\/td><td>Alcyone\u202fTherapeutics, Massachusetts<\/td><\/tr><tr><td><strong>Key Asset<\/strong><\/td><td>ThecaFlex\u202fDRx implant\u2011catheter system<\/td><\/tr><tr><td><strong>Lead Company<\/strong><\/td><td>Biogen (end\u2011to\u2011end development, manufacturing, commercialization)<\/td><\/tr><tr><td><strong>Initial Use<\/strong><\/td><td>Biogen\u2019s <strong>SPINRAZA<\/strong> (nusinersen) for spinal muscular atrophy (SMA)<\/td><\/tr><tr><td><strong>Future Scope<\/strong><\/td><td>Expansion to Biogen\u2019s investigational ASO pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-integration-amp-workforce\">Integration &amp; Workforce<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alcyone Talent<\/strong> \u2013 Alcyone employees will join Biogen\u2019s <strong>Product Delivery Solutions<\/strong> team, strengthening expertise in device\u2011centric development.<\/li>\n\n\n\n<li><strong>Manufacturing Infrastructure<\/strong> \u2013 Biogen will leverage its existing manufacturing capabilities to scale ThecaFlex\u202fDRx production.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SMA Treatment Landscape<\/strong> \u2013 ThecaFlex\u202fDRx could set a new standard for SMA care, potentially reducing procedural burden and associated costs.<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong> \u2013 By offering a unique delivery platform, Biogen positions itself ahead of rivals that rely solely on conventional lumbar puncture or infusion systems.<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong> \u2013 Early alignment with FDA and EMA guidelines for device\u2011drug combinations is expected to accelerate market entry.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts\u2011based Alcyone Therapeutics. The deal centers on&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41974,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4362,351,993,24,64],"class_list":["post-41971","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-alcyone-therapeutics","tag-biogen","tag-nasdaq-biib","tag-rare-orphan-disease-drugs","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts\u2011based Alcyone Therapeutics. The deal centers on the joint development of ThecaFlex\u202fDRx, an investigational implantable subcutaneous port\u2011catheter system designed for intrathecal delivery of antisense oligonucleotide (ASO) therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41971\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts\u2011based Alcyone Therapeutics. The deal centers on the joint development of ThecaFlex\u202fDRx, an investigational implantable subcutaneous port\u2011catheter system designed for intrathecal delivery of antisense oligonucleotide (ASO) therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41971\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-22T07:13:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-22T07:13:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2205.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development\",\"datePublished\":\"2025-09-22T07:13:05+00:00\",\"dateModified\":\"2025-09-22T07:13:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971\"},\"wordCount\":258,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2205.webp\",\"keywords\":[\"Alcyone Therapeutics\",\"Biogen\",\"NASDAQ: BIIB\",\"Rare \\\/ orphan disease drugs\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41971#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41971\",\"name\":\"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2205.webp\",\"datePublished\":\"2025-09-22T07:13:05+00:00\",\"dateModified\":\"2025-09-22T07:13:06+00:00\",\"description\":\"Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts\u2011based Alcyone Therapeutics. The deal centers on the joint development of ThecaFlex\u202fDRx, an investigational implantable subcutaneous port\u2011catheter system designed for intrathecal delivery of antisense oligonucleotide (ASO) therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41971\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2205.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2205.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41971#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts\u2011based Alcyone Therapeutics. The deal centers on the joint development of ThecaFlex\u202fDRx, an investigational implantable subcutaneous port\u2011catheter system designed for intrathecal delivery of antisense oligonucleotide (ASO) therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41971","og_locale":"en_US","og_type":"article","og_title":"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development","og_description":"Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts\u2011based Alcyone Therapeutics. The deal centers on the joint development of ThecaFlex\u202fDRx, an investigational implantable subcutaneous port\u2011catheter system designed for intrathecal delivery of antisense oligonucleotide (ASO) therapies.","og_url":"https:\/\/flcube.com\/?p=41971","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-22T07:13:05+00:00","article_modified_time":"2025-09-22T07:13:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2205.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41971#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41971"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development","datePublished":"2025-09-22T07:13:05+00:00","dateModified":"2025-09-22T07:13:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41971"},"wordCount":258,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41971#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2205.webp","keywords":["Alcyone Therapeutics","Biogen","NASDAQ: BIIB","Rare \/ orphan disease drugs","RNAi \/ ASO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41971#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41971","url":"https:\/\/flcube.com\/?p=41971","name":"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41971#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41971#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2205.webp","datePublished":"2025-09-22T07:13:05+00:00","dateModified":"2025-09-22T07:13:06+00:00","description":"Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts\u2011based Alcyone Therapeutics. The deal centers on the joint development of ThecaFlex\u202fDRx, an investigational implantable subcutaneous port\u2011catheter system designed for intrathecal delivery of antisense oligonucleotide (ASO) therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41971#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41971"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41971#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2205.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2205.webp","width":1080,"height":608,"caption":"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41971#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex\u202fDRx Implant Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2205.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41971"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41971\/revisions"}],"predecessor-version":[{"id":41975,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41971\/revisions\/41975"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41974"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}